Medical management of both conditions can be complicated, because RA disease activity and the use of glucocorticoids, csDMARDs and bDMARDs (often in combination) to treat RA may affect glucose levels through their effects on glucose metabolism, insulin sensitivity and pancreatic β cell function [3, 24, 25, 36]. This evidence concerns the gene INS and rheumatoid arthritis.